UCB SA (OTCMKTS:UCBJF) Short Interest Down 51.3% in November

UCB SA (OTCMKTS:UCBJF) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 313,600 shares, a drop of 51.3% from the November 15th total of 643,700 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 1,568.0 days.

UCB Price Performance

Shares of UCBJF remained flat at $174.00 during trading on Friday. The firm’s fifty day simple moving average is $179.93 and its 200 day simple moving average is $163.22. UCB has a 1 year low of $73.54 and a 1 year high of $194.76. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.